Antonio Cigliola

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Journal: Expert review of anticancer therapy

Published: June 30, 2026

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center.

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center.

Journal: World journal of urology

Published: June 19, 2026

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

Journal: European urology

Published: May 19, 2026

Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence.

Prognostic Impact of Initial Management Strategies in Metachronous Oligometastatic Renal Cell Carcinoma: A Real-World Evidence.

Journal: Clinical genitourinary cancer

Published: May 11, 2026

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter.

Journal: Clinical genitourinary cancer

Published: May 07, 2026

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Journal: Clinical genitourinary cancer

Published: May 03, 2026

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.

Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.

Journal: ESMO open

Published: April 13, 2026

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods.

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods.

Journal: ESMO open

Published: February 22, 2026

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

Journal: Bladder cancer (Amsterdam, Netherlands)

Published: January 09, 2026

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.

Journal: European urology oncology

Published: December 18, 2025

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.

Journal: The oncologist

Published: December 08, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026